After reporting positive top-line results from a make-or-break Phase III trial of macitentan in PAH, Actelion Ltd.'s to do list hasn't gotten any shorter. The company must translate the data into regulatory approval and a competitive label, while addressing its shrinking pipeline.

While details on the data won't be revealed until 2H12, investors may learn the company's strategy for replenishing its pipeline as soon as Tuesday this week.